Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.
Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.
Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1.
Sinopia Biosciences Inc. has entered into a target discovery collaboration with Ono Pharmaceutical Co. Ltd. focused on a group of rare metabolic disorders with significant unmet medical need.
Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.
Ono Pharmaceutical Co. Ltd. has entered into an agreement to expand its drug discovery collaboration agreement with Congruence Therapeutics Inc. for the discovery of novel small-molecule modulators against multiple protein targets in the areas of neurology and immunology.
Cure Rare Disease has entered into a multiyear partnership with the LGMD2L Foundation to develop a gene replacement therapy for anoctamin 5 (ANO5)-related disease, a rare genetic disorder.
Angelini Pharma SpA and Quiver Bioscience Inc. have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Under the multiyear collaboration, Angelini Pharma will leverage Quiver’s technology platform to gain deeper understanding of a broad set of developmental and epileptic encephalopathies.
Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.
Nektar Therapeutics Inc. has established an academic research collaboration with the University of California, San Francisco (UCSF) to explore the role of tumor necrosis factor receptor 2 (TNFR2) agonism in models of multiple sclerosis (MS) with the aim of supporting progression of NKTR-0165, Nektar’s first-in-class TNFR2 agonist antibody.
RSS
